The primary therapeutic role of Лактинет (Desogestrel) is applied across domains where additional symptomatic support is needed, and its unique composition makes it relevant for specific patient groups and management of certain symptom patterns. The medication is explicitly indicated for pregnancy prevention.

---

Clinical Applications

This medication is commonly used across conditions characterized by periods of heightened symptoms where ongoing birth control is appropriate, and is considered relevant in contexts requiring estrogen avoidance. This is applicable in scenarios such as during the postpartum period or when a patient is lactating. For these patients, the progestogen-only composition is considered relevant for symptomatic management, supporting their specific health management needs.

Quick Fact: Support for Reproductive Health

Domain	Primary Therapeutic Use
Core Indication	Pregnancy Prevention (Contraception)
Special Context	Estrogen Avoidance (e.g., breastfeeding, high blood pressure)
Supportive Benefit	Menstrual Symptom Management (easing heavy flow/discomfort)

The medication may assist with managing the burden of symptoms related to physical discomfort, which may be associated with lighter bleeding or the absence of periods, thereby contributing to improved comfort during symptomatic periods.

Eligibility Map: Who Can and Cannot Use Лактинет — Official Regulatory Information

Лактинет (Desogestrel) is a progestogen-only contraceptive intended for women of reproductive age seeking pregnancy prevention. Its use is strictly regulated by official contraindications and specific population-based restrictions.

---

Eligibility Status	Populations / Conditions
Contraindicated (Absolute Prohibition)	Known or suspected pregnancy; Active venous thromboembolic disorder; Sex-steroid sensitive malignancies (e.g., breast cancer); History of severe hepatic disease with abnormal liver function; Undiagnosed vaginal bleeding; Hypersensitivity to components.
Permitted (Conditional Use)	Lactating Women (Breastfeeding Women). Use is permitted, but the growth and development of the nursing infant should be carefully observed.
Restricted (Requires Observation/Discontinuation)	Patients with diabetes mellitus (requires observation); Women who develop sustained hypertension (may require discontinuation); History of thrombo-embolic disorders (requires careful observation).
Age-Related Eligibility	Intended for use after menarche; Not indicated for use in elderly or post-menopausal women.

---

Official Eligibility Statements:

• The medicine is contraindicated in cases of severe hepatic disease and active venous thromboembolic disorder.
• Use is contraindicated during pregnancy, but may be used during lactation.
• Patients with diabetes or a tendency toward chloasma require special observation or conditional restrictions (e.g., avoiding UV radiation).

These regulatory classifications establish mandatory exclusions related to vascular health, hormone-sensitive cancer history, and liver function, defining precisely who can and who cannot use the medicine.

Interactions with other medicines and products

Official regulatory documentation identifies several categories of medicines and substances that interact with the active component, Desogestrel, primarily through effects on drug metabolism.

Interaction Classifications

Classification	Interacting Entity	Interaction Description
Contraindicated Combination	HCV Regimens (Ombitasvir/Paritaprevir/Ritonavir pm Dasabuvir)	Formal prohibition due to documented risk of increased liver enzyme (ALT) elevations.
Reduced Exposure/Efficacy	Hepatic Enzyme Inducers (e.g., Carbamazepine, Phenytoin, Rifampicin, St. John’s Wort)	Decreases the plasma concentration of etonogestrel, which may compromise contraceptive effectiveness.
Altered Exposure of Co-drug	Ciclosporin, Lamotrigine	Documented to either increase (Ciclosporin) or decrease (Lamotrigine) the plasma concentration of the co-administered medicine.

Official Interaction Statements

• The co-administration with specific Hepatitis C Virus combination drug regimens is strictly contraindicated based on official label restrictions.
• Co-use with strong enzyme-inducing medicines results in a pharmacokinetic interaction that reduces the systemic exposure of the contraceptive hormone.
• Following the use of the emergency contraceptive Ulipristal acetate, official guidance mandates that the initiation of Desogestrel must be delayed for five days.
• Conditions such as severe malabsorption syndromes are noted in regulatory information as potentially reducing tablet absorption, which is functionally equivalent to an exposure-modifying interaction.

This structure reflects the constraints and required monitoring established by national and intergovernmental health authorities.

The Mechanism of Action of Лактинет

Лактинет's action is mediated by its active metabolite, etonogestrel, which acts as a selective agonist of the progesterone receptor (PR). This binding initiates distinct intracellular signaling sequences that suppress the normal cyclic hormonal release.

The mechanism primarily involves strong negative feedback on the hypothalamic-pituitary (H-P) axis. This antigonadotropic influence suppresses the release of pituitary gonadotropins, specifically blunting the mid-cycle surge of Luteinizing Hormone (LH). This modification of the regulatory cascade results in the system-level physiological consequence of inhibiting follicular development.

Simultaneously, etonogestrel modulates pathways in the reproductive tract periphery. It induces a marked increase in the viscosity and thickness of the cervical mucus and causes structural and functional alteration of the endometrium.

How to Use Лактинет: Administration Guidelines

Лактинет is a progestogen-only oral contraceptive that is used according to a strict, continuous daily regimen. The medication is administered via the oral route as a 75 mcg film-coated tablet containing the active ingredient, Desogestrel.

Standard Dosing and Schedule

The standard dosage for contraception is one tablet daily. The treatment is continuous, requiring that the tablet be taken at about the same time every day to maintain a consistent 24-hour interval between doses. Crucially, there is no tablet-free interval; a new 28-day pack must be started immediately on the day after the previous pack is finished.

Administration Context and Missed Doses

To ensure proper administration, the tablet should be swallowed whole, optionally with a small amount of liquid, and must be taken in the order indicated on the blister pack.

There is a 12-hour grace period for a missed dose. If the tablet is taken more than 12 hours late (i.e., the interval exceeds 36 hours), contraceptive protection may be reduced. In this event, the user takes the missed tablet immediately and uses an additional barrier method of contraception for the next seven consecutive days.

Initiation Protocols

The protocol for starting the medication varies based on the patient's context. For instance, following delivery or a second-trimester abortion, tablet-taking is advised to begin between Day 21 and Day 28. If initiation occurs after Day 28, the use of an additional barrier method is required for the first seven days of treatment.

Research evidence / Overview of studies for Лактинет

This section provides an overview of the official research and clinical studies conducted on the active ingredient in Лактинет (Desogestrel), detailing the types of research, what was studied, and where uncertainties remain, consistent with scientific guidelines.

---

Evidence for use in Pregnancy Prevention (Contraception)

Research has explored studies in the context of pregnancy prevention. Studies conducted include Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews that combine data from multiple clinical settings. Research examined the potential for preventing pregnancy, tracked by measurements like the Pearl Index. Studies also monitored a key biological outcome: the inhibition of ovulation.

The research so far indicates that studies monitoring consistent use over up to one year reported measurements related to pregnancy rates in the observed populations. Clinical trials described the measurement of ovulation inhibition markers in most treated cycles. Findings also described patterns observed in some studies regarding the menstrual bleeding of users, noting that some experienced amenorrhea (absence of bleeding) or infrequent bleeding.

Evidence in Contexts Requiring Estrogen Avoidance

Research has explored this medicine in specific patient groups who need to avoid estrogen, such as women who are in the postpartum period or who are actively breastfeeding (lactating). Systematic reviews and non-randomized prospective studies were evaluated in these populations. Studies focused on outcomes related to infant growth and development and breastfeeding performance, including milk volume and composition. Research examined the transfer of the active hormone into breast milk to track infant exposure levels.

Findings indicate that studies reported measurements of normal growth and development parameters in infants whose mothers used Desogestrel during lactation. The consolidated data show patterns related to the duration of breastfeeding and milk volume, and research did not report negative patterns when compared to non-hormonal methods.

What is Still Uncertain About the Research Base

While the core indication is well-studied, key research limitations remain. Long-term effects are not fully established beyond the one-year follow-up period. Follow-up durations were limited in many pivotal trials, and comparative evidence is lacking for certain endpoints when comparing Desogestrel against all available contraceptive methods. Overall, evidence highlights what is known—and what is still uncertain—and research does not determine whether an individual will respond similarly, as study results reflect the conditions under which they were conducted.

Common questions about Лактинет (FAQ)

Q: What is the maximum daily dose of this medicine for adults?

A: Official regulatory documents indicate that for adults and children 12 years and older, product labels commonly cite a maximum daily intake of 4,000 mg (4 grams) of acetaminophen from all sources within a 24-hour period. It is important that this limit is not exceeded. Individuals with pre-existing conditions, such as liver disease, may have a lower maximum dose and are advised to discuss use with a healthcare professional.

Q: What should I avoid taking with this medicine?

A: Regulatory product information states that you should not take this product with any other medicine containing acetaminophen (APAP) to help prevent the risk of accidental overdose. Furthermore, individuals are advised to discuss use with a healthcare professional if they are currently taking the blood-thinning medication warfarin or if they consume three or more alcoholic drinks every day.

Q: Does this medicine cause any allergic or serious skin reactions?

A: According to official regulatory sources, acetaminophen has been associated rarely with serious skin reactions, including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Acute Generalized Exanthematous Pustulosis (AGEP), which can be fatal. Allergic reactions (e.g., swelling, difficulty breathing, or hives) may also occur. It is important to stop using the medicine and seek emergency medical help immediately if a skin rash or any sign of an allergic reaction is noticed.

Q: Can I take this medicine if I have liver disease?

A: Regulatory documents state that this medicine is generally not recommended for individuals with severe active liver disease or severe hepatic impairment. If you have any history of liver issues, including chronic alcohol use, it is advised to consult a healthcare professional before using this medicine, as the risk of serious liver injury may be increased.

Q: Can I use this medicine for a headache?

A: Official information indicates that acetaminophen is an analgesic, or pain reliever, and is officially used to temporarily relieve minor aches and pains, which includes relief from a headache.

Q: How should I store this medicine?

A: Official guidance recommends storing the medicine in its original container, ensuring it is tightly closed, at room temperature (typically between 20-25°C or 68-77°F). It should be kept away from excess heat and moisture, which means avoiding storage in places like the bathroom. The medication should always be kept out of the sight and reach of children.

Q: Can I take this medicine for arthritis pain?

A: Regulatory documents list the temporary relief of minor aches and pains as an approved use, and this includes pain associated with minor arthritis.

Q: Does this medicine make you feel tired or sleepy?

A: Official product information for single-ingredient acetaminophen generally indicates that it is not expected to impair the ability to drive or operate machinery. Extreme tiredness or sleepiness are not typically listed as common side effects but may be symptoms associated with an overdose.

Q: Is it safe to take this medicine long-term?

A: Regulatory documents recommend that use should not extend beyond a few days for fever or a maximum of ten days for pain without prior consultation with a healthcare professional. Prolonged, regular daily use of acetaminophen has been noted to potentially increase the effect of the blood thinner warfarin, which may raise the risk of bleeding.

Q: Can this medicine be used by children 6 months old?

A: Acetaminophen products are commonly available for infants and children, and the product label provides specific instructions for use based on age and weight. A child-specific formulation should be used, and it is essential to consult a healthcare professional for accurate, weight-based dosing.

How to Store and Dispose of Лактинет?

The official requirements for storing and disposing of Лактинет (Desogestrel) are defined to ensure product stability and public safety, based on government regulatory labeling.

Official Storage Conditions

Requirement	Specific Rule
Temperature	Do not store above 30 C.
Protection	Must be kept protected from light.
Packaging	Keep the blister pack in the original outer carton to maintain stability.

It is mandatory to keep this medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Лактинет must not be thrown away with household waste or disposed of in wastewater. Official instructions require patients to ask a pharmacist how to properly discard the medicine, ensuring disposal complies with local pharmaceutical waste regulations.